Skip to main content


Generic name: ocrelizumab
Dosage form: intravenous (infusion) injection
Drug class: CD20 monoclonal antibodies

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 4, 2023.

What is Ocrevus?

Ocrevus (ocrelizumab) is a monoclonal antibody used for the treatment of a central nervous system (CNS) disorder called multiple sclerosis (MS).

It's not known exactly how Ocrevus works in people with MS, but it targets and binds to B-cells expressing CD20 on their surface, which results in their destruction via antibody-dependent cellular cytolysis and complement-mediate lysis. B cells are a type of white blood cell that contributes to the development and ongoing disease process involved in MS in a number of ways. The CD20 antigen is mainly found on the surface of B cells, which are also known as B lymphocytes, making it a good target for MS and certain other conditions affecting B cells.

Ocrevus was approved by the US Food and Drug Administration (FDA) in March 2017.

What is Ocrevus used for?

Ocrevus is a prescription medicine used to treat:

It is not known if it is safe and effective in children.

Important information

Ocrevus can cause serious side effects, including:

See "What are the possible side effects of Ocrevus?" below for more information about side effects.

Who should not receive Ocrevus?

What should I tell my doctor before receiving Ocrevus?

Before receiving Ocrevus, tell your healthcare provider about all of your medical conditions, including if you:

How should I receive Ocrevus?

What happens if I miss a dose?

If you miss a dose of Ocrevus, call your healthcare provider and reschedule your appointment to receive your missed dose as soon as possible. Do not wait until your next planned dose. After you receive your missed dose, reschedule your next dose for 6 months after your missed dose. Ocrevus doses must be separated by a minimum of 5 months.

Dosing information

The recommended dose of Ocrevus is:

See Full Prescribing Information for further details about Ocrevus dosing.

What are the side effects of Ocrevus?

Ocrevus may cause serious side effects, including:

These are not all the possible side effects of this medication. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider about other immunosuppressive or immune-modulating drugs that you have taken or are currently taking.

Pregnancy and breastfeeding

Tell you healthcare provider if you are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if Ocrevus will harm your unborn baby. You should use birth control (contraception) during treatment with this medication and for 6 months after your last infusion. Talk with your healthcare provider about what birth control method is right for you during this time.

There is a pregnancy registry for women who take Ocrevus during pregnancy. If you become pregnant while receiving this medication, tell your healthcare provider right away. Talk to your healthcare provider about registering with the Ocrevus Pregnancy Registry. The purpose of this registry is to collect information about your health and your baby's health. Your healthcare provider can enroll you in this registry by calling 1-833-872-4370 or visiting

If you have a baby and you received Ocrevus during your pregnancy, it is important to tell your baby's healthcare provider about receiving this medication so they can decide when your baby should be vaccinated.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if Ocrevus passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take this medication.


Keep out of sight and reach of children.

What are the ingredients in Ocrevus?

Active ingredient: ocrelizumab.

Inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate trihydrate, trehalose dihydrate.

Ocrevus is manufactured b: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990.

Popular FAQ

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

In patients with relapsing forms of multiple sclerosis, Kesimpta (ofatumumab) is thought to be more effective than Ocrevus (ocrelizumab) in some ways, but no clinical trials have directly compared the two drugs

Ocrevus is the only one of the two drugs approved to treat primary progressive multiple sclerosis Continue reading

Ocrevus costs approximately $20,769 for one 300 mg/10mL vial depending on the pharmacy you visit and based on using the discount card. Most people do not pay for the full cost of Ocrevus. This price is for cash paying customers and is not valid with insurance plans. People with commercial or private insurance may be eligible for Ocrevus Co-Pay assistance and pay as little as $0 per infusion. Co-pay assistance is provided up to $1,500 per calendar year in the first year and up to $1,000 each calendar year after. Continue reading

Ocrevus has some effect at reducing disability progression within about 12 weeks; however, it may take at least 6 months or possibly longer for the full effects to be seen. Continue reading

Ocrevus is not chemotherapy, it is a type of targeted treatment that works by binding to a protein called CD20 that is present on the surface of B-lymphocytes. Ocrevus may be used to reduce inflammation, reduce the risk of relapse, and delay the rate of disease progression in people with multiple sclerosis.

Continue reading

The first two times you have Ocrevus it will be infused over at least 2.5 hours, depending on how you tolerate it. However, the whole infusion appointment will take around 5 to 6 hours, because there is a pre-infusion check-up, during which you will receive medications that reduce infusion reactions, and you will need to wait for at least an hour post-infusion so your healthcare team can monitor you for any side effects or infusion reactions. Continue reading

Ocrevus works in MS by targeting a specific protein, called CD20 that exists on the surface of immature and mature B-lymphocytes. B lymphocytes are a type of white blood cell which are thought to contribute to the development of MS in several different ways, including secreting antibodies during an MS attack that cause inflammation which damages the myelin coating around nerve cells in the brain and spinal cord. When Ocrevus binds to CD20, it causes B-cells to self-destruct or disintegrate, which reduces the number of MS relapse and the rate of disability progression. Continue reading

Ocrevus (ocrelizumab) is the first treatment approved for primary progressive multiple sclerosis (PPMS). It is also approved for the more common relapsing forms of multiple sclerosis. Continue reading

More FAQ

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.